Physician profile
James P Perry
NPI 1235132325
$2,809.14
in general payments reported to CMS, 2019-2025
25 companies · $32.92 in 2025
The $32.92 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,447 · 2020: $83.40 · 2022: $519 · 2023: $449 · 2024: $278 · 2025: $32.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,082.65 | 2019-2023 | Da Vinci Surgical System |
| Hologic Sales and Service, LLC | $462.74 | 2019-2024 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $247.22 | 2019-2025 | |
| Abbvie INC. | $180.11 | 2019-2024 | |
| Coopersurgical, INC. | $105.26 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $84.92 | 2022-2024 | |
| Medtronic, INC. | $72.82 | 2022 | |
| Astellas Pharma US INC | $68.60 | 2023-2024 | Veozah |
| Merck Sharp & Dohme LLC | $58.73 | 2019-2020 | |
| Duchesnay USA Incorporated | $48.68 | 2019 | |
| Allergan, INC. | $44.08 | 2019 | |
| Roche Diagnostics Corporation | $43.91 | 2019 | |
| Therapeuticsmd, INC. | $40.50 | 2022 | |
| Minerva Surgical, INC | $40.12 | 2019-2022 | |
| Coloplast Corp | $29.80 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $29.09 | 2019-2025 | Slynd |
| Covidien LP | $28.16 | 2020 | |
| Pharmacosmos Therapeutics INC. | $24.13 | 2023 | Monoferric |
| Sumitomo Pharma America, INC. | $22.13 | 2024 | Myfembree |
| Mayne Pharma Commercial LLC | $21.57 | 2022 | |
| Meditrina | $18.11 | 2023 | |
| Shield Therapeutics INC | $16.79 | 2023 | Accrufer |
| Vertical Pharmaceuticals, LLC | $15.33 | 2019 | |
| Sanara Medtech INC. | $13.75 | 2022 | |
| Organon LLC | $9.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.